MDxHealth SA is a precision diagnostics company that focuses on developing and commercializing innovative molecular tests to support the diagnosis, prognosis, and monitoring of cancer. Through its proprietary technology and advanced genomic profiling, the company aims to provide healthcare professionals with critical insights into patient conditions, ultimately enhancing personalized treatment strategies. MDxHealth’s products are designed to improve patient outcomes by offering more accurate and reliable information that assists in clinical decision-making in oncology. Read More
Mdxhealth Announces Peer-Reviewed Publication of Oxford GPS-ProMPT Study in European Urology Oncology, Establishing Scientific Foundation for the Landmark GPS-ProtecT Randomized Controlled Trial
MDxHealth (NASDAQ:MDXH) reported first-quarter 2026 revenue of $27.4 million while announcing a strategic exit from its Resolve UTI testing business and the planned closure of its Plano, Texas, laboratory facility, a move executives said will sharpen the company’s focus on prostate cancer diagnostic
Mdxhealth Highlights Data from Oxford’s ProMPT Study Demonstrating the Genomic Prostate Score GPS Test Predicts Adverse Outcomes Across Multiple Treatment Settings at EAU 2026
Mdxhealth and University of Oxford to validate GPS test in largest randomized trial of treatment effectiveness in patients with localized prostate cancer
